<ѻý>Transplant With Orca-T Reduced GVHD in Hematologic Malignanciesѻý> Risk of relapse was also lower in the group who received the cell therapy Oct 03, 2022
<ѻý>Response-Based Ponatinib Dose Reduction a Win-Win in Chronic-Phase CML?ѻý> Strategy applied in OPTIC trial may mitigate adverse events without sacrificing benefit Sep 29, 2022
<ѻý>Magrolimab-Azacitidine Shows Promise in Untreated High-Risk MDSѻý> About a third of patients, including those with TP53 mutations, achieved complete remission Sep 29, 2022
<ѻý>'Unparalleled Times' in Hematology, but Workforce Issues Persistѻý> "This is the most exciting time ever" to be a hematologist, says ASH President Jane Winter, MD Sep 26, 2022 video
<ѻý>What's on Tap at the Society of Hematologic Oncology's 10th Annual Meetingѻý> Emphasis on novel biological approaches in treating patients with hematologic malignancies Sep 26, 2022
<ѻý>CAR-T Therapy Effective in Youngest Kids With ALLѻý> Analysis shows safety and outcomes equivalent to those reported in older children Sep 08, 2022
<ѻý>Low-Dose Hypomethylating Agents in Lower-Risk MDS Yield Promising Outcomesѻý> Overall response rates were 67% with decitabine, 48% with azacitidine Aug 22, 2022
<ѻý>Two More Patients With HIV Surviving Without Antiretroviralsѻý> Functional cures now seen in 5 patients Jul 29, 2022
<ѻý>'Rogue' Online Pharmacies Are Dispensing Cancer Drugsѻý> Shady sites with little oversight are selling imatinib for much less than U.S. retail price Jul 29, 2022
<ѻý>Zanubrutinib Wins in First-Line CLL for Older Patientsѻý> The BTK inhibitor proves superior to bendamustine-rituximab in phase III trial Jul 08, 2022
<ѻý>FDA Warns of Increased Mortality Risk With Duvelisibѻý> Drug approved for adults with CLL/SLL Jul 01, 2022
<ѻý>FDA Panel Backs Gene Tx for Degenerative Brain Disorder in Kidsѻý> Advisers unanimously recommend approval for pediatric ALD patients without HLA-matched donors Jun 10, 2022
<ѻý>FDA Pulls Lymphoma Approvals for PI3K Inhibitor Umbralisibѻý> Worse overall survival observed despite improvements in progression-free survival Jun 01, 2022
<ѻý>Allo-Transplant With Omidubicel Hints at Longer-Term Benefits Tooѻý> "Viable" option for patients eligible for umbilical cord blood transplantation, investigator says Apr 27, 2022
<ѻý>Eprenetapopt-Based Combo Impresses in TP53-Mutant AML/MDSѻý> 1-year relapse-free survival rate of 60% with maintenance therapy after transplant Apr 25, 2022
<ѻý>9/11 Responders More Likely to Carry Genetic Mutations Tied to Cancerѻý> Clonal hematopoiesis seen in 10% of firefighters, medical personnel on the scene after WTC attack Mar 07, 2022
<ѻý>Third Person 'Cured' of HIV via Transplantѻý> U.S. woman with leukemia gets cord blood resistant to HIV Feb 16, 2022
<ѻý>Women More Likely to Experience Severe Toxicity of Cancer Treatmentsѻý> Increased risk was particularly pronounced among those receiving immunotherapy Feb 14, 2022
<ѻý>Illusionist Criss Angel's Son's Acute Leukemiaѻý> Famed magician speaks about the long battle Feb 09, 2022
<ѻý>Targeted Agent Improves Survival in FLT3-Positive Acute Myeloid Leukemiaѻý> OS, EFS improved versus historical controls with addition of midostaurin to chemotherapy Dec 17, 2021
<ѻý>Another Study Reinforces Chemo-Free Therapy for Newly Diagnosed CLLѻý> Ibrutinib-rituximab extends PFS versus chemoimmunotherapy, especially in unmutated disease Dec 16, 2021
<ѻý>Can Dasatinib Dose Be Halved in Low-Risk CML?ѻý> Lower dose associated with improved tolerability, similar responses in propensity score analysis Dec 14, 2021
<ѻý>Gentler Regimen Leads to High Response Rate in Older Patients With B-Cell ALLѻý> One-year OS rate of 78% with fractionated inotuzumab ozogamicin exceeds 60% historical rate Dec 13, 2021
<ѻý>Venetoclax Regimens for 'Fit' CLL Yield High Undetectable MRD Ratesѻý> Combined with obinutuzumab, plus or minus ibrutinib, outperforms chemoimmunotherapy Dec 13, 2021
<ѻý>Upfront IDH1 Inhibitor Triples Survival in Older AMLѻý> Median OS for ivosidenib-azacitidine reached 2 years in patients ineligible for intensive therapy Dec 11, 2021
<ѻý>Next-Gen MRD Testing Predicts Acute Leukemia Relapse After CAR-Tѻý> Nearly all patients with detectable disease relapsed or progressed to transplant, other therapies Dec 01, 2021
<ѻý>Novel Triplet Yields Undetectable MRD Status in 90% of CLL/SLL Patientsѻý> Zanubrutinib plus obinutuzumab and venetoclax was also well tolerated Nov 29, 2021
<ѻý>Pegylated Interferon Wins FDA Approval for Polycythemia Veraѻý> Majority of patients attained complete hematologic response with ropeginterferon alfa-2b Nov 15, 2021
<ѻý>A Gentler Standard for Acute Promyelocytic Leukemia in Kidsѻý> ATRA/arsenic trioxide without maintenance therapy resulted in 99-100% survival at 2 years Nov 11, 2021
<ѻý>FDA Approves STAMP Inhibitor for Chronic Myeloid Leukemiaѻý> Patients treated with two or more TKIs and those with T315I mutation gain new option Nov 01, 2021
<ѻý>What Happens When All the Great Doctors Are Gone?ѻý> In commemoration of the late Elihu (Eli) Estey, MD Oct 13, 2021
<ѻý>Life Expectancy Still Lower for Blood or Marrow Transplant Recipientsѻý> Although late mortality has decreased over the past 40 years Sep 09, 2021
<ѻý>Anti-CD7 CAR-T Therapy Yields High Response Rate in Acute Leukemiaѻý> Complete responses in 18 of 20 patients with relapsed/refractory T-cell ALL Aug 04, 2021
<ѻý>Add-On Venetoclax Promising in Younger, Fit AML Patientsѻý> "Safe and feasible intensive regimen" in small single-center study Jul 30, 2021
<ѻý>IVF Babies at No Increased Risk of Childhood Cancersѻý> No associations seen with intracytoplasmic sperm injection or frozen embryo transfer, study found Jul 02, 2021
<ѻý>Ethics Consult: Help Family Have 'Savior Child' for Marrow Donation? MD/JD Weighs Inѻý> You voted, now see the results and an expert's discussion Jun 25, 2021
<ѻý>Fixed-Duration, All-Oral Regimen Slows CLL Progressionѻý> Near-80% reduction in PFS hazard with ibrutinib-venetoclax versus obinutuzumab-chlorambucil Jun 16, 2021
<ѻý>Zanubrutinib Tops Ibrutinib in Relapsed or Refractory CLLѻý> Better overall response rate, less cardiotoxicity, with second-generation BTK inhibitor Jun 14, 2021
<ѻý>COVID Vaccine Protection; 'Until You Die From the Cancer'; What's Palliative Care?ѻý> News, features, and commentary about cancer-related issues Jun 10, 2021
<ѻý>Acalabrutinib Offers Less Wear and Tear on the Heart in CLL Patientsѻý> BTK inhibitor had less cardiotoxicity than ibrutinib, but similar efficacy Jun 07, 2021